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Abstract: Cytotoxic necrotizing factor 1 (CNF1) is a bacterial protein toxin primarily expressed
by pathogenic Escherichia coli strains, causing extraintestinal infections. The toxin is believed
to enhance the invasiveness of E. coli by modulating the activity of Rho GTPases in host cells,
but it has interestingly also been shown to promote inflammation, stimulate host immunity and
function as a potent immunoadjuvant. The mechanisms underlying the immunostimulatory
properties of CNF1 are, however, poorly characterized, and little is known about the direct effects
of the toxin on immune cells. Here, we show that CNF1 induces expression of maturation
markers on human immature monocyte-derived dendritic cells (moDCs) without compromising
cell viability. Consistent with the phenotypic maturation, CNF1 further triggered secretion of
proinflammatory cytokines and increased the capacity of moDCs to stimulate proliferation of
allogenic naïve CD4+ T cells. A catalytically inactive form of the toxin did not induce moDC
maturation, indicating that the enzymatic activity of CNF1 triggers immature moDCs to undergo
phenotypic and functional maturation. As the maturation of dendritic cells plays a central role in
initiating inflammation and activating the adaptive immune response, the present findings shed new
light on the immunostimulatory properties of CNF1 and may explain why the toxin functions as
an immunoadjuvant.
Keywords: CNF1; bacterial toxins; dendritic cells; moDCs; Rho GTPases; cytokine expression;
T-cell activation; inflammation; anti-virulence immunity; effector-triggered immunity
1. Introduction
Cytotoxic necrotizing factor 1 (CNF1) is a bacterial protein toxin produced by certain strains of
pathogenic Escherichia coli. cnf1-positive E. coli have been isolated from children with diarrhea, but are
most frequently associated with extraintestinal conditions, such as urinary tract infections, bacteremia
and neonatal meningitis [1]. E. coli strains harboring the gene for CNF1 have also been isolated from
skin and soft tissue infections, suggesting that the toxin may function as a virulence factor in diverse
host niches [2]. After bacterial secretion, CNF1 enters host cells by receptor-mediated endocytosis [3].
Two cellular receptors have so far been shown to mediate CNF1 internalization; the 37/67 kDa laminin
receptor and the Lutheran adhesion glycoprotein/basal cell adhesion molecule (Lu/BCAM) [4–7].
Following endocytosis, endosomal acidification and cleavage of CNF1 leads to translocation of the
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active part of the toxin into the cytoplasm where it deamidates a specific glutamine residue in Rho
GTPase proteins. This modification impairs the intrinsic GTP hydrolyzing activity of Rho GTPases
and thereby locks them in their active state. The Rho GTPases control a wide range of cellular
processes but are best recognized for their central role in regulating the dynamics and organization
of the actin cytoskeleton. Accordingly, CNF1 induces rearrangements of the actin cytoskeleton in
target cells, leading to morphological and functional changes. These rearrangements can facilitate
bacterial internalization into host cells, and substantial evidence supports that CNF1 contributes to the
invasiveness of pathogenic E. coli by manipulating the epithelial and endothelial barriers [3,8,9].
Infection studies have further reported that CNF1 has the capacity to promote inflammation in vivo,
indicating that the toxin also possesses immunostimulatory properties [10–13]. In line with this conclusion,
CNF1 has been shown to be a potent immunoadjuvant that can augment antigen-specific adaptive
immune responses and host protection [14–16]. A catalytically inactive variant of CNF1, where cysteine
866 has been mutated into a serine residue (CNF1-C866S), is devoid of immunoadjuvant properties,
suggesting that the immunostimulatory capacity of the toxin is linked to its enzymatic activity [14,15].
Boyer and co-workers accordingly demonstrated that CNF1-mediated activation of the Rho GTPase Rac2
elicited an inflammatory response in Drosophila melanogaster that promoted eradication of pathogenic
E. coli [17]. In addition, Diabate et al. found that cnf1-positive E. coli were cleared faster from the blood
of bacteremic mice than isogenic cnf1-negative E. coli or E. coli expressing CNF1-C866S [18]. The rapid
clearance of cnf1-positive E. coli was associated with improved survival of the mice and enhanced levels of
cytokines, chemokines and Gr1-positive immune cells (e.g., granulocytes and inflammatory monocytes) in
the blood. Antibody-mediated depletion of Gr1-positive cells was sufficient to block the eradication of
E. coli during bacteremia and prevent the CNF1-induced bacterial clearance. CNF1 was further shown to
potentiate lipopolysaccharide (LPS)-triggered expression of cytokines and chemokines from monocytes
in vitro. These findings suggest a scenario in which CNF1 enhances the expression of inflammatory
factors from activated monocytes leading to increased mobilization of Gr1-positive cells and thereby more
effective clearance of bacteria in the bloodstream [18,19]. Accumulating data thus indicate that CNF1
activity stimulates a protective inflammatory response in host organisms. However, the mechanisms that
contribute to CNF1-induced tissue inflammation remain unclear, and little is known about the direct effects
of the toxin on different immune cell subsets.
Dendritic cells (DCs) are innate immune cells that play a pivotal role in stimulating the inflammatory
response against intruding pathogens and activating adaptive immunity. They exist in two distinct
functional and phenotypic states, known as immature and mature. Immature DCs are widely distributed
throughout the body, where they function as key sentinels of infection in tissues and at mucosal surfaces.
In the immature state, DCs are generally tolerogenic, but upon sensing invading microbes, they are
activated to undergo a maturation process where they upregulate expression of major histocompatibility
complex (MHC) and co-stimulatory molecules to become potent antigen-presenting cells that are highly
efficient at activating naïve T cells. Furthermore, activated DCs secrete inflammatory cytokines that
contribute to the activation and recruitment of various immune cells and regulate naïve T cell differentiation.
Immature DCs can sense invading microbes via a battery of pattern recognition receptors (PRRs) that
recognize specific microbe-associated molecular patterns (MAMPs) [20–22]. MAMPs are, however, present
in both pathogenic and non-pathogenic microbes, implying that DCs employ additional mechanisms to
discriminate between them. Although this phenomenon remains poorly characterized in DCs, a growing
body of evidence supports that host cells may assess the pathogenic potential of bacteria by sensing
virulence factor- and toxin-induced manipulation of fundamental cellular processes [23]. Given the
reported immunostimulatory properties of CNF1, we therefore investigated the capacity of the toxin to
induce activation and maturation of monocyte-derived DCs (moDCs).
2. Results
To address whether CNF1 induces DC maturation, we initially cultured human immature moDCs
with different concentrations of wild-type or catalytically inactive CNF1 (CNF1-C866S) for 24 or 48 h
Int. J. Mol. Sci. 2018, 19, 1408 3 of 11
and analyzed the surface expression of the two classic DC maturation markers CD83 and CD86.
Importantly, CNF1 triggered a dose- and time-dependent increase in the percentage of CD83 and
CD86 double-positive cells when compared to immature moDCs cultured without toxin (Figure 1A,B).
Furthermore, CNF1 induced increased surface expression of HLA-DR MHC class II molecules in a similar
dose- and time-dependent fashion, collectively demonstrating that the toxin elicits phenotypic maturation
of immature moDCs (Figure 1C). The moDCs exhibited a remarkable sensitivity to CNF1; relative to
immature moDCs cultured without toxin, as little as 20 pM CNF1 induced a strong and significant increase
in the percentage of CD83 and CD86 double-positive cells within 48 h of culture (Figure 1A,B). In contrast,
CNF1-C866S had no significant impact on the expression of the analyzed maturation markers, indicating
that CNF1 triggers moDC maturation via its catalytic activity (Figure 1A–C).
Figure 1. Cytotoxic necrotizing factor 1 (CNF1), but not CNF1-C866S, induces phenotypic maturation
of immature monocyte-derived dendritic cells (moDCs). (A–C) Immature moDCs were cultured for
24 and 48 h without toxin (Ctrl) or with different concentrations of CNF1 or CNF1-C866S before the
expression of phenotypic maturation markers was measured by flow cytometry. (A) Representative
pseudocolor dot plot showing surface expression of CD83 and CD86. (B) Graphs summarizing the
mean percentages of CD83+CD86+ cells from 3 independent experiments, each using moDCs derived
from different donors (n = 3). Error bars represent SEM and * denotes a significant difference (p < 0.05)
compared to immature moDCs cultured without toxin using a two-way ANOVA with Sidak’s multiple
comparisons test. (C) Histogram plots showing the surface expression of HLA-DR on moDCs cultured
without toxin (green), with CNF1 (red) or with CNF1-C866S (blue). Arrows indicate increasing
concentrations (0.004, 0.02 and 0.1 nM) of CNF1 and CNF1-C866S. The plots are representative of
3 independent experiments each using moDCs derived from different donors (n = 3).
Products purified from Gram-negative bacteria can contain substantial levels of endotoxin (LPS),
which is a potent inducer of moDC maturation. It was therefore essential to confirm that the observed
maturation of moDCs was mediated specifically by CNF1 and not due to LPS contamination of the
toxin preparation. To this end, we employed the polypeptide antibiotic Polymyxin B (PMB), which binds
to and neutralizes LPS with very high affinity [24]. As judged by the frequency of CD83 and CD86
double-positive cells, PMB completely blocked LPS-induced maturation of moDCs, whereas it had
no significant effect on cytokine-induced (TNFα) or, importantly, CNF1-induced moDC maturation
(Figure 2A). While this result provided evidence that the CNF1-induced maturation of moDCs was not
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due to the presence of LPS in the CNF1 toxin preparation, it did not exclude that it could be caused by
other putative bacterial contaminants. We therefore diluted the CNF1 toxin preparation in culture media
and incubated aliquots with uncoated agarose beads, agarose beads coated with a specific antibody against
CNF1 or agarose beads coated with an isotype control antibody. As a negative control, culture media
without CNF1 was incubated with uncoated agarose beads. The agarose beads were subsequently removed
by centrifugation and, as anticipated, agarose beads coated with CNF1-specific antibody depleted CNF1
from the toxin preparation when compared to aliquots incubated with uncoated agarose beads or agarose
beads coated with isotype control antibody (Figure 2B). Depletion of CNF1 from the toxin preparation
strikingly abrogated its capacity to induce CD83 and CD86 expression on immature moDCs whereas toxin
preparations that had been incubated with uncoated agarose beads or agarose beads coated with isotype
control antibody retained their ability to trigger moDC maturation (Figure 2C). Altogether, these results
strongly support that the observed maturation of moDCs was mediated specifically by CNF1 and not by
LPS or other putative contaminants in the toxin preparation. This conclusion was further corroborated by
our prior data, showing that CNF1, but not CNF1-C866S, triggered moDCs maturation even though the
toxins were purified using the same procedure (Figure 1).
Figure 2. CNF1-induced moDC maturation is not driven by endotoxin or other putative contaminants
in the toxin preparation. (A) Culture media alone (Ctrl) or culture media containing 0.1 nM CNF1,
50 ng/mL lipopolysaccharide (LPS) or 50 ng/mL tumor necrosis factor alpha (TNFα) was pre-incubated
for 30 min at room temperature with 5 µg/mL Polymyxin B (PMB) or vehicle (endotoxin-free water).
Then, immature moDCs were added to each media sample and cultured for 24 h before the
expression of CD83 and CD86 was determined by flow cytometry. Shown is the mean percentage
of CD83+CD86+ moDCs from 4 different donors (n = 4) analyzed in 3 independent experiments.
Error bars represent SEM and * denotes a significant difference (p < 0.05) between vehicle- and
PMB-treated cells using a paired Student’s t-test. (B) CNF1 diluted in moDC medium was incubated
with (2) uncoated Protein A agarose beads or (3) Protein A agarose beads that had been pre-coated with
a monoclonal anti-CNF1 (αCNF1) antibody or (4) an isotype control (IC) antibody. As a negative control,
(1) moDC medium without CNF1 was in parallel incubated with uncoated Protein A agarose beads.
After removal of the beads, the level of CNF1 in the supernatants was analyzed by western blotting.
(C) Immature moDCs were cultured for 24 h with the supernatants (1–4) obtained in (B) and the
expression of CD83 and CD86 analyzed by flow cytometry.
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CNF1 was originally reported to be cytotoxic but it has subsequently become clear that the toxin,
in most cases, promotes the survival of target cells [25]. To asses if CNF1 influenced the viability of
moDCs, we analyzed the percentage of cells positive for the apoptotic marker Annexin V and the
cell death marker propidium iodide (PI) after 24 and 48 h of culture with 0.1 nM CNF1. As shown
in Figure 3, CNF1 did not increase the percentage of Annexin V- and/or PI-positive cells relative to
immature DCs cultured without toxin. In contrast, a significant increase in the percentage of Annexin
V- and/or PI-positive cells was observed in starved immature moDCs cultured without serum and
cytokines (Figure 3). These results indicate that CNF1-mediated maturation of moDCs is not an indirect
consequence of compromised cell viability.
Figure 3. CNF1 does not induce apoptosis or cell death in moDCs. (A,B) Immature moDCs were
cultured for 24 and 48 h without toxin (Ctrl) or with 0.1 nM CNF1 before the percentages of Annexin
V- and propidium iodide (PI)-positive cells were determined by flow cytometry. moDCs cultured
in medium without fetal bovine serum and cytokines (Starved) were included in the analysis as
a positive control for induction of apoptotic cell death. (A) Histogram summarizing the mean
percentages of Annexin V+ and/or PI+ cells from 3 independent experiments, each using moDCs
derived from different donors (n = 3). Error bars represent SEM and * denotes a significant difference
(p < 0.05) compared to Ctrl moDCs at the same timepoint using a two-tailed paired Student’s t-test.
(B) A representative pseudocolor dot plot of an Annexin V and PI staining after 48 h of culture.
Based on our findings, it was fundamental to establish if the phenotypic maturation of immature
moDCs was accompanied by functional activation and maturation. A hallmark of activated DCs is
that they secrete proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor
alpha (TNFα) [22]. In keeping with the phenotypic maturation, supernatants from immature moDCs
cultured with CNF1 contained highly increased levels of both IL-6 and TNFα when compared to
supernatants from immature moDCs cultured without CNF1 or with CNF1-C866S (Figure 4A,B).
Another key functional characteristic of mature moDCs is that they are potent in inducing activation
and proliferation of naïve CD4+ T cells. Therefore, we investigated the capacity of moDCs that had
been cultured with CNF1, CNF1-C866S or as a positive control LPS to induce proliferation of naïve
CD4+ T cells isolated from allogenic healthy donors. As shown in Figure 4C, moDCs that had been
treated with CNF1 exhibited significantly increased capacity to induce proliferation of allogenic naïve
CD4+ T cells relative to moDCs that had been treated with CNF1-C866S or cultured without toxin.
Collectively, these findings strongly suggest that CNF1 activity activates immature moDCs to undergo
phenotypic and functional maturation.
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Figure 4. CNF1 induces functional maturation of moDCs. (A,B) Immature moDCs were cultured for
24 h without toxin (Ctrl), with 0.1 nM CNF1 or with 0.1 nM CNF1-C866S before the concentrations
of (A) interleukin-6 (IL-6) and (B) TNFα in the cell culture supernatants were determined by
enzyme-linked immunosorbent assay (ELISA). (A,B) Shown is the mean cytokine concentration + SEM
in cell culture supernatants from 3 independent experiments each using moDCs derived from different
donors (n = 3). (C) Immature moDCs were cultured for 48 h with 0.1 nM CNF1, 0.1 nM CNF1-C866S,
50 ng/mL LPS or without toxin (Ctrl). The moDCs were subsequently washed and different numbers
cultured with allogenic naïve CD4+ T cells for 4 days. Then [3H]-thymidine was added, and the
cells cultured for 24 h further, before determination of [3H]-thymidine incorporation. Shown are the
mean counts per minute (CPM) from 3 independent experiments. Each independent experiment was
performed using moDCs and allogenic naïve CD4+ T cells derived from different donors (total of
6 donors). Error bars represent SEM and * denotes a significant difference (p < 0.05) compared to
CD4+ T cells cultured with the same number of Ctrl moDCs using a two-way ANOVA with Sidak’s
multiple comparisons test.
3. Discussion
In recent years, pioneering studies have provided evidence that CNF1 has the capacity to
promote inflammation, stimulate host immunity and function as a potent immunoadjuvant [10–18].
Nevertheless, the immunostimulatory properties of the toxin are not fully understood and little is
known about its direct effects on different immune cell subsets. Here, we show that CNF1 potently
triggers activation and maturation of immature human moDCs. CNF1-induced moDC maturation
was not associated with increased levels of apoptotic or dead cells, strongly arguing that it was not
an indirect effect of compromised cell viability. In contrast to CNF1, the catalytically inactive form
of the toxin, CNF1-C866S, failed to trigger moDC maturation. These findings are consistent with
prior studies demonstrating that CNF1, but not CNF1-C866S, promotes anti-bacterial immunity and
immunization in vivo and supports that the immunostimulatory properties of the toxin are linked to
its enzymatic activity [14,15,17,18]. Notably, Diabate et al. found that CNF1 potentiated LPS-induced
expression of IL-6 and TNFα from murine monocytes, but that the toxin was unable to trigger secretion
of the cytokines in itself [18]. Our results suggest that CNF1 has the capacity to induce secretion of
these cytokines from human moDCs independently of LPS, implying that there may be differences
in how the inflammatory response to CNF1 is regulated in monocytes and moDCs—or alternatively,
in murine and human cells.
The experimental use of primary DCs is limited, due to their severe paucity in peripheral blood,
and therefore in vitro-generated moDCs are commonly used as a model [26]. While classical DCs (cDC)
are the best characterized, moDCs also represent an important immune cell subset in vivo where they
differentiate from circulating monocytes that extravasate from the blood into tissues. Relatively few
moDCs are present in tissues and at mucosal surfaces in steady state conditions but their abundance
increases drastically during inflammation [21,27]. Once activated, moDCs can remain in the inflamed
tissue producing cytokines, killing bacteria and driving local T cell responses or travel to the draining
lymph nodes where they may contribute to the activation and differentiation of naïve T cells [21].
It has been proposed that cDCs are central in the initial phase of the inflammatory response, leading
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to the mobilization of moDCs that are critical for effective clearance of the pathogen in subsequent
phases [28]. Although care should be taken when extrapolating findings from moDCs to cDCs,
we speculate that CNF1 activity also triggers activation and maturation of cDCs. As cnf1-positive
E. coli strains are generally invasive and capable of infecting diverse host niches, it seems plausible that
analogous to monocytes in the blood, DC subsets have the capacity to sense CNF1 activity in tissues
and secondary lymphoid organs and in turn promote a protective immune reaction [2,18]. It should,
however, be highlighted that CNF1 has also been shown to increase the activity of natural killer cells
and to induce secretion of inflammatory factors from endothelial and epithelial cell lines, indicating
that several cell types may contribute to CNF1-induced inflammation [29–31].
Tissue infiltration of CNF1-expressing bacteria would not only expose DCs to the toxin,
but concurrently to a variety of other bacterial factors with the capacity to promote or inhibit DC
activation and maturation. Integration of diverse bacteria- and host-induced signals is therefore
expected to influence CNF1-driven DC activation in vivo. In line with this idea, Diabate et al.
showed that the toxin, α-Hemolysin can protect E. coli against CNF1-induced host responses [18].
As α-Hemolysin is often co-expressed with CNF1, this finding interestingly indicates that E. coli have
evolved strategies to subvert the immunostimulatory properties of CNF1 during infection.
CNF1 is not unique in its ability to tamper with Rho GTPase activity in host cells. Manipulation of
Rho GTPase signaling is a conserved strategy utilized by a variety of pathogens to promote invasion
and dissemination in the host organism. For example, Salmonella enterica serovar Typhimurium
expresses the effector protein SopE, which activates Rho GTPases in host cells by serving as
a nucleotide-exchange factor [32]. Keestra et al. interestingly demonstrated that SopE-mediated
activation of the Rho GTPases Rac1 and Cdc42 triggered the NOD1 signaling pathway in the
human embryonic kidney cell line HEK293, eventually leading to activation of the proinflammatory
transcription factor NF-κB [33]. Whereas a mutant sopE-deficient S. typhimurium strain did not
elicit remarkable caecal inflammation, sopE-proficient S. typhimurium induced colitis in wild-type
mice, but not in Nod1-deficient mice [33]. Indeed, accumulating evidence suggest that excessive
Rho GTPase activation provoked by bacterial virulence factors induces formation of a multiprotein
complex, involving NOD1 and RIP kinases, which triggers NF-κB activation and cytokine expression.
This mechanism is primarily derived from experiments using epithelial cells, but it is feasible that
a similar pathway is implicated in CNF1-mediated activation of moDCs. Our findings thus feed into
emerging data suggesting that animal cells, similar to effector-triggered immunity in plants, can sense
pathogen-induced manipulation of Rho GTPase activity as a danger signal [23,34].
In conclusion, we provide novel evidence showing that CNF1 induces activation and maturation
of moDCs. This finding sheds new light on the immunostimulatory properties of CNF1 and supports
future prospects for its clinical application as an adjuvant in DC-based vaccines.
4. Materials and Methods
4.1. Purification of CNF1 and CNF1-C866S
CNF1 was obtained from the 392 ISS E. coli strain (kindly provided by Vincenzo Falbo
(Istituto Superiore di Sanita, Rome, Italy), and the plasmid coding for CNF1-C866S was a kind gift from
Emmanuel Lemichez (Inserm, Nice, France). Both toxins were purified as previously described [8].
The final working concentrations were obtained in Tris-HCl buffer, pH 7.5.
4.2. Purification of PBMCs and Generation of Immature moDCs
Peripheral blood mononuclear cells (PBMCs) were isolated by Lymphoprep™ (Axis-Shield,
Oslo, Norway) density gradient centrifugation from buffy coats that were obtained from healthy
blood donors at the Danish Blood Bank (Department of Clinical Immunology, University Hospital
Rigshospitalet, Copenhagen, Denmark). Ethical approval was waived by “Den Videnskabsetiske
Komité Københavns og Frederiksberg Kommuner”, which deemed that no results obtained in the
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experiments were related to the donors, and no samples or cells were stored; samples were identified
by date of blood sampling only, and analyzed anonymously. Verbal consent to blood sampling
was considered adequate by the Ethics Committee, and was obtained. Monocytes were purified
from the PBMCs by negative selection using the Human MACS Monocyte Isolation Kit II from
Miltenyi Biotec (Bergisch Gladbach, Germany). The purified monocytes were cultured for 5 days
(37 ◦C and 5% CO2) in moDC media (RPMI-1640 AQmedia (Sigma-Aldrich, St. Louis, MO, USA),
100 µg/mL penicillin/streptomycin (Sigma-Aldrich) and 10% endotoxin-low fetal bovine serum (FBS)
(ThermoFisher Scientific, Gibco, Waltham, MA, USA)) supplemented with 50 ng/mL recombinant
GM-CSF (PeproTech, London, UK) and IL-4 (PeproTech) to generate immature moDCs. The immature
moDCs were finally washed and cultured in fresh moDC media supplemented with 50 ng/mL GM-CSF
for 24 and/or 48 h in absence (Ctrl) or presence of CNF1, CNF1-C866S, LPS (Sigma-Aldrich), TNFα
(PeproTech) or PMB (InvivoGen, San Diego, CA, USA) as indicated prior analysis.
4.3. Flow Cytometry
For analysis of maturation markers, cells were resuspended in ice-cold FACS buffer (5% FBS
and 0.1% Na-azide in phosphate buffered saline (PBS)) containing diluted mouse serum (Agilent,
Santa Clara, CA, USA), stained with BV421-conjugated anti-CD83 (BioLegend, San Diego, CA, USA),
APC conjugated anti-CD86 (BioLegend) and PE-conjugated anti-HLA-DR (Leinco, St. Louis, MO, USA)
antibodies for 30 min at 4 ◦C in the dark, washed with FACS buffer and subjected to flow cytometric
acquisition. For viability analysis, cells were resuspended in Annexin V Binding Buffer (BioLegend)
and stained for 15 min with PE-conjugated Annexin V (BD Biosciences, Franklin Lakes, NJ, USA)
at 4 ◦C in the dark. PI (Biolegend) was subsequently added and the cells subjected to flow cytometric
acquisition which was performed at the CFFC (Core Facility for Flow Cytometry, Faculty of Health
and Medical Sciences, University of Copenhagen) using a Fortessa 3 flow cytometer (BD Biosciences).
The acquired data were analyzed with FlowJo v10 software (Tree Star, Ashland, OR, USA).
4.4. CNF1 Depletion
Protein A-agarose macrobeads (Sigma-Aldrich) were coated overnight at 4 ◦C with an anti-CNF1
antibody (Clone NG8, Hycult Biotech, Plymouth Meeting, PA, USA), an IgG2a isotype control antibody
(R&D systems, Minneapolis, MN, USA) or PBS as control. The beads were then washed extensively
with PBS and incubated overnight at 4 ◦C with CNF1 diluted in moDC media. As a negative control,
moDC media without CNF1 was incubated in parallel with uncoated control beads. The beads were
subsequently pelleted by centrifugation and the supernatants transferred to new tubes before they were
incubated with fresh Protein A-agarose macrobeads for 1 h at 4 ◦C to remove any residual antibody.
After removal of the beads, a portion of the supernatants was boiled in reducing sodium dodecyl
sulfate sample buffer and analyzed by western blotting, as previously described [35]. The remaining
of the supernatants were added to immature moDCs which were analyzed for the expression of CD83
and CD86 after 24 h of culture.
4.5. ELISA
The concentrations of IL-6 and TNFα in cell culture supernatants were measured using
cytokine-specific human DuoSet Enzyme-Linked Immunosorbent Assay (ELISA) development kits
from R&D Systems in accordance with the manufacturer’s instructions.
4.6. moDC-Induced Proliferation of Allogenic Naïve CD4+ T Cells
Immature moDCs were cultured in moDC media with 50 ng/mL GM-CSF for 48 h in absence or
presence of 0.1 nM CNF1, 0.1 nM CNF1-C866S or 50 ng/mL LPS. The moDCs were subsequently washed
and different numbers cultured in X-VIVO 15 media (Lonza, Basel, Switzerland) together with 5 × 104
naïve CD4+ T cells freshly purified from PBMCs from healthy allogenic donors using the Human Naïve
CD4+ T cell Isolation Kit II from Miltenyi Biotec. After 4 days of culture, 5 µCi/mL [3H]-thymidine
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(GE Healthcare, Chicago, IL, USA) was added to each sample. The cells were incubated for 24 h further
before they were harvested onto UniFilter plates (PerkinElmer, Waltham, MA, USA). Finally, Microscint-20
cocktail (PerkinElmer) was added to the UniFilter plates prior to analysis in a TopCount®NXT Microplate
Scintillation and Luminescence Counter (PerkinElmer). The [3H]-thymidine incorporation was measured
as mean counts per minute (CPM) from three replicate cultures.
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Abbreviations
CNF1 Cytotoxic necrotizing factor 1
DCs Dendritic cells
MAMPs Microbe-associated molecular patterns
moDCs Monocyte-derived DCs
PMB Polymyxin B
LPS Lipopolysaccharide
cDCs Classical DCs
PBMCs Peripheral blood mononuclear cells
IL-6 Interleukin-6
TNFα Tumor necrosis factor alpha
PBS Phosphate buffered saline
PI Propidium iodide
MHC Major histocompatibility complex
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